Biggest News Aggregation in the World
📰 Ongoing Phase News

Page 4 - Ongoing Phase News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Ongoing Phase. Real-time updates on events, politics, business and more.

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from Its KER-050 Program and Preclinical Data from Its Alk2 Inhibitor Program At the 28Th Annual Congress of the European Hematology Association

Keros Therapeutics, Inc. announced that it presented additional data from its ongoing Phase 2 clinical trial of KER-050 in patients with very low-, low-, or intermediate-risk myelodysplastic syndromes... | June 10, 2023
European Hematology Association Keros Therapeutics Inc Keros Therapeutics Annual Congress Ongoing Phase

Protagonist Therapeutics, Inc.: Protagonist Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at 2023 European Hematology Association Congress

NEWARK, CA / ACCESSWIRE / June 6, 2023 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that a late-breaking abstract featuring blinded, randomized withdrawal
Mecklenburg Vorpommern Jami Taylor Arturo Molina Marina Kremyanskaya Andrew Kuykendall Stefan Klotter

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Coave Therapeutics announces Positive 12-months Data from Ongoing Phase I/II Clinical Trial of CTx-PDE6b in Patients with Retinitis Pigmentosa Caused

Coave Therapeutics announces Positive 12-months Data from Ongoing Phase I/II Clinical Trial of CTx-PDE6b in Patients with Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b -        CTx-PDE6b demonstrated clinically meaningful benefit in visual functions at the highe...
France General Coave Therapeuticsannounces Positive Ongoing Phase Retinitis Pigmentosa Caused Bi Allelic Mutations Retinitis Pigmentosa

FORE Biotherapeutics to Present Promising New Data from Phase 1/2a Trial Evaluating Plixorafenib (FORE8394) in Patients With BRAF-Altered Advanced Solid and Central Nervous System Tumors at ASCO 2023

Positive data support the potential of plixorafenib to induce deep and durable benefit for patients with BRAF-mutated (V600+) cancers In the V600+ population benefit was observed in both MAPK-inhibitor
United States Gewinn Nur Deric Sherman American Society Of Clinical Oncology Physician At Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center

Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors

Encouraging preliminary anti-tumor activity observed in a patient with PD-L1 negative advanced non-small cell lung cancer Favorable preliminary safety profile for XTX101 observed at the recommended... | May 25, 2023
Melissa Forst Martin Huber Clinical Development Plan Linkedin Xilio Therapeutics Inc Exchange Commission Ongoing Phase

Rocket Pharmaceuticals Presents Positive Data from LV Hematology and AAV Cardiovascular Gene Therapy Programs at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

Robust and sustained efficacy in both adult PKD patients up to 30 months post-RP-L301; first pediatric patient results suggest efficacy similar to adult cohort with initial greater than five-point... | May 19, 2023
United States State Of California Investigaciones Energ Los Angeles Enfermedades Raras Kaplan Meier

Atossa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update

Two Phase 2 trials investigating -endoxifen in neoadjuvant setting initiated and are enrolling patientsFull enrollment of Phase 2 KARISMA mammographic breast density study expected by end of 2023Ended... | May 15, 2023
United States Kyle Guse Eric Van Zanten Foundation For The National Institutes Of Health Cancer Biomarkers Consortium Atossa Therapeutics Inc

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science